دورية أكاديمية
أعرض في EDS

TCR clonotypes modulate the protective effect of HLA class I molecules in HIV-1 infection.

التفاصيل البيبلوغرافية
العنوان: TCR clonotypes modulate the protective effect of HLA class I molecules in HIV-1 infection.
المؤلفون: Chen H; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Boston, Massachusetts, USA., Ndhlovu ZM, Liu D, Porter LC, Fang JW, Darko S, Brockman MA, Miura T, Brumme ZL, Schneidewind A, Piechocka-Trocha A, Cesa KT, Sela J, Cung TD, Toth I, Pereyra F, Yu XG, Douek DC, Kaufmann DE, Allen TM, Walker BD
المصدر: Nature immunology [Nat Immunol] 2012 Jun 10; Vol. 13 (7), pp. 691-700. Date of Electronic Publication: 2012 Jun 10.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Nature America Inc Country of Publication: United States NLM ID: 100941354 Publication Model: Electronic Cited Medium: Internet ISSN: 1529-2916 (Electronic) Linking ISSN: 15292908 NLM ISO Abbreviation: Nat Immunol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: New York, NY : Nature America Inc. c2000-
مواضيع طبية MeSH: HIV Infections/*immunology , HIV-1/*immunology , HLA-B Antigens/*immunology , HLA-B27 Antigen/*immunology , Receptors, Antigen, T-Cell/*immunology, CD8-Positive T-Lymphocytes/immunology ; CD8-Positive T-Lymphocytes/virology ; Cells, Cultured ; Epitopes, T-Lymphocyte/immunology ; HIV Infections/blood ; HIV Infections/virology ; HIV Long-Term Survivors ; Humans ; Perforin/immunology ; Virus Replication/immunology ; gag Gene Products, Human Immunodeficiency Virus/immunology
مستخلص: The human leukocyte antigens HLA-B27 and HLA-B57 are associated with protection against progression of disease that results from infection with human immunodeficiency virus type 1 (HIV-1), yet most people with alleles encoding HLA-B27 and HLA-B57 are unable to control HIV-1. Here we found that HLA-B27-restricted CD8(+) T cells in people able to control infection with HIV-1 (controllers) and those who progress to disease after infection with HIV-1 (progressors) differed in their ability to inhibit viral replication through targeting of the immunodominant epitope of group-associated antigen (Gag) of HIV-1. This was associated with distinct T cell antigen receptor (TCR) clonotypes, characterized by superior control of HIV-1 replication in vitro, greater cross-reactivity to epitope variants and enhanced loading and delivery of perforin. We also observed clonotype-specific differences in antiviral efficacy for an immunodominant HLA-B57-restricted response in controllers and progressors. Thus, the efficacy of such so-called 'protective alleles' is modulated by specific TCR clonotypes selected during natural infection, which provides a functional explanation for divergent HIV-1 outcomes.
التعليقات: Comment in: Nat Immunol. 2012 Jul;13(7):632-4. (PMID: 22713821)
References: Immunity. 2008 Dec 19;29(6):1009-21. (PMID: 19062316)
Nature. 2001 Mar 1;410(6824):106-11. (PMID: 11242051)
J Virol. 2001 Dec;75(24):11983-91. (PMID: 11711588)
J Virol. 2008 Sep;82(17):8422-30. (PMID: 18562530)
Annu Rev Med. 2003;54:535-51. (PMID: 12525683)
J Clin Invest. 2011 Nov;121(11):4322-31. (PMID: 21965332)
J Exp Med. 2004 Dec 20;200(12):1547-57. (PMID: 15596521)
PLoS Pathog. 2010 May 27;6(5):e1000917. (PMID: 20523897)
Blood. 2006 Jun 15;107(12):4781-9. (PMID: 16467198)
Blood. 2009 Jun 18;113(25):6351-60. (PMID: 19389882)
Nat Immunol. 2007 Nov;8(11):1246-54. (PMID: 17906628)
J Virol. 2003 Feb;77(3):2081-92. (PMID: 12525643)
J Virol. 2008 Jun;82(11):5594-605. (PMID: 18385228)
JAMA. 2010 Jul 14;304(2):194-201. (PMID: 20628133)
Proc Natl Acad Sci U S A. 2011 Jul 12;108(28):11530-5. (PMID: 21690407)
Proc Natl Acad Sci U S A. 1989 Dec;86(23):9514-8. (PMID: 2480604)
J Virol. 2007 May;81(10):4973-80. (PMID: 17329324)
J Infect Dis. 2008 Feb 15;197(4):563-71. (PMID: 18275276)
J Virol. 2009 Mar;83(6):2743-55. (PMID: 19116253)
J Virol. 2012 Apr;86(7):4014-8. (PMID: 22278241)
J Immunol. 2011 Apr 1;186(7):4285-94. (PMID: 21383244)
J Infect Dis. 1995 Jul;172(1):88-96. (PMID: 7541065)
Eur J Immunol. 2005 Feb;35(2):341-51. (PMID: 15657948)
J Exp Med. 2009 Apr 13;206(4):923-36. (PMID: 19349463)
Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2709-14. (PMID: 10694578)
Immunity. 2009 Jul 17;31(1):99-109. (PMID: 19592272)
Immunity. 2007 Sep;27(3):406-16. (PMID: 17892849)
Nat Med. 2007 Jan;13(1):46-53. (PMID: 17173051)
Science. 2010 Dec 10;330(6010):1551-7. (PMID: 21051598)
Nature. 2010 May 20;465(7296):350-4. (PMID: 20445539)
Nat Med. 2011 Jul 17;17(8):989-95. (PMID: 21765403)
PLoS Pathog. 2009 Apr;5(4):e1000377. (PMID: 19360131)
Blood. 2011 Aug 25;118(8):2138-49. (PMID: 21734237)
J Virol. 2007 Jan;81(1):434-8. (PMID: 17050606)
J Virol. 2009 Apr;83(7):3138-49. (PMID: 19158248)
Nature. 2006 Sep 21;443(7109):350-4. (PMID: 16921384)
J Immunol. 2008 Apr 1;180(7):5092-100. (PMID: 18354235)
J Virol Methods. 2006 Feb;131(2):134-42. (PMID: 16182382)
Nat Immunol. 2002 Nov;3(11):1061-8. (PMID: 12368910)
Nat Med. 1996 Apr;2(4):405-11. (PMID: 8597949)
Science. 2003 Nov 14;302(5648):1218-22. (PMID: 14512504)
Nat Med. 1997 Feb;3(2):212-7. (PMID: 9018241)
J Exp Med. 2007 Oct 1;204(10):2473-85. (PMID: 17893201)
Nature. 2001 Jul 19;412(6844):334-8. (PMID: 11460164)
Immunol Cell Biol. 2011 Mar;89(3):375-87. (PMID: 21301479)
J Immunol. 2003 Oct 1;171(7):3718-24. (PMID: 14500671)
J Immunol. 2011 Jan 1;186(1):359-71. (PMID: 21135165)
J Virol. 2004 Jul;78(13):7069-78. (PMID: 15194783)
Clin Infect Dis. 2010 Jul 15;51(2):233-8. (PMID: 20550452)
J Exp Med. 1997 Nov 3;186(9):1407-18. (PMID: 9348298)
معلومات مُعتمدة: Canada CAPMC CIHR; United States HHMI Howard Hughes Medical Institute; 5 P30 AI060354-04 United States AI NIAID NIH HHS; AI030914 United States AI NIAID NIH HHS; AI074415 United States AI NIAID NIH HHS; United States ImNIH Intramural NIH HHS; R01 AI130197 United States AI NIAID NIH HHS; P30 AI060354 United States AI NIAID NIH HHS; R01 AI030914 United States AI NIAID NIH HHS; R21 AI129594 United States AI NIAID NIH HHS; P01 AI074415 United States AI NIAID NIH HHS; R21 AI124769 United States AI NIAID NIH HHS
المشرفين على المادة: 0 (Epitopes, T-Lymphocyte)
0 (HLA-B Antigens)
0 (HLA-B27 Antigen)
0 (HLA-B57 antigen)
0 (Receptors, Antigen, T-Cell)
0 (gag Gene Products, Human Immunodeficiency Virus)
126465-35-8 (Perforin)
تواريخ الأحداث: Date Created: 20120612 Date Completed: 20120907 Latest Revision: 20211214
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC3538851
DOI: 10.1038/ni.2342
PMID: 22683743
قاعدة البيانات: MEDLINE
الوصف
تدمد:1529-2916
DOI:10.1038/ni.2342